unv502 2.9

Excerpt One major policy focus in the US has been to reform the regulatory requirements for prescribing buprenorphine for OUD. Requirements for getting a federal waiver have been characterized as a barrier to care, marginalizing OUD care from mainstream medicine and disincentivizing health professionals from learning about and engaging in buprenorphine prescribing ( Fiscella et al., 2019 ). Policy advocates have noted the dissonance of requiring such regulation for buprenorphine when no such requirements are in place for the equally, or potentially more, risky full opioid agonists that are widely prescribed for the treatment of pain Wakeman and Barnett, (2018) . This culminated at the end of 2022 in the passage of the federal Mainstreaming Addiction Treatment Act , which officially abolished the federal waiver. This policy intervention has been described by federal drug administrators, bipartisan lawmakers, and physicians as “life-saving” and “historic” in closing the addiction treatment gap ( The White House, 2023 ). Paraphrase Reforming the legal prerequisites for prescribing buprenophine for the treatment of opioid use disorder has been a primary area of policy concern in the United States. Stipulated mandates to receive a federal waiver are described as a hindrance to care, diminishing treatment for opioid use disorders from conventional medicine and discouraging medical authorities from becoming knowledgeable about and practicing buprenorphine medication (Hurst, 2002). Proponents of policy have pointed out the contradiction in mandating regulations for buprenorphine while leaving the equally, or possibly more hazardous full opioid agonists, which are commonly administered for pain management, unregulated. The federal waiver was formally removed at the end of 2022 with the approval of the federal Mainstreaming Addiction Treatment Act. Physicians, political lawmakers, and federal drug administrators have hailed this policy action in closing the gap in addiction treatment as a momentous and life-saving (Hurst, 2002). Hurst, E. (2002, December). Online access available for all via ScienceDirect. Composites Science and Technology, 62 (16), 2085-2086. https://doi.org/10.1016/s0266- 3538(02)00205-1 REPLY  o JC Jason Crook replied toKatherine Hedrick Nov 12, 2023, 10:33 AM Hey Katherine, I was reading recently that the DEA was making it more difficult for patients to get buprenorphine by putting in place stricter regulations. Have you seen anything about this lately? The DEA passed laws